前收市價 | 368.84 |
開市 | 371.57 |
買盤 | 180.00 x 900 |
賣出價 | 587.60 x 1100 |
今日波幅 | 365.79 - 373.45 |
52 週波幅 | 205.10 - 403.44 |
成交量 | |
平均成交量 | 291,391 |
市值 | 17.564B |
Beta 值 (5 年,每月) | 0.91 |
市盈率 (最近 12 個月) | 25.80 |
每股盈利 (最近 12 個月) | 14.24 |
業績公佈日 | 2024年4月25日 |
遠期股息及收益率 | 3.40 (0.92%) |
除息日 | 2024年2月15日 |
1 年預測目標價 | 412.89 |
Danaher's (DHR) Q1 earnings are likely to be hurt by weakness in the Biotechnology unit. Improving supply chains and strong price realization are expected to be positives.
Recently, Zacks.com users have been paying close attention to Carlisle (CSL). This makes it worthwhile to examine what the stock has in store.
According to the average brokerage recommendation (ABR), one should invest in Carlisle (CSL). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?